Private Advisor Group, LLC Lineage Cell Therapeutics, Inc. Transaction History
Private Advisor Group, LLC
- $17.5 Billion
- Q2 2025
A detailed history of Private Advisor Group, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Private Advisor Group, LLC holds 20,058 shares of LCTX stock, worth $33,697. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,058
Previous 20,058
-0.0%
Holding current value
$33,697
Previous $9,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
139Shares Held
106MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$83.3 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$16.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$14.3 Million0.0% of portfolio
-
Defender Capital, Llc.6.79MShares$11.4 Million2.42% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$9.06 Million6.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $285M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...